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Abstract
A 9-year-old girl, treated for growth hormone deficiency, developed bitemporal progressive
headache, diplopia, acute comitant esotropia and visual loss 3 months after starting recombinant
growth hormone. An increased intracranial pressure was revealed by examination of ocular fundus
and lumbar puncture, and the absence of other causes, ruled out through a brain scan, led to the
diagnosis of idiopathic intracranial hypertension.
Recombinant growth hormone was discontinued and acetazolamide started up to 30 mg/kg/die
without any clinical improvement but developing metabolic acidosis. The switch to intravenous
dexamethasone (0.4 mg/kg/die) led to a dramatic clinical improvement after only 1 day, then
confirmed by examination of ocular fundus and visual evoked potentials. Currently, there are no
evidence-based guidelines for the management of intracranial hypertension, and even though
acetazolamide is recognized as the first-line drug, its efficacy and safety have not been proven: some
patients might not respond and others will present unacceptable side-effects. Therefore we suggest
the use of corticosteroids in intracranial hypertension when acetazolamide is inefficient or
intolerable.
Case presentation
We report a case of a 9-year-old Caucasian Italian girl,
treated for growth hormone deficiency (GHD) with
recombinant human growth hormone (rhGH) at a total
weekly dose of 6 mg. At the diagnosis of GHD her weight
was 24.6 kg, her height was 113 cm; physical examination,
mental and developmental status were all normal. The
diagnosis was made on laboratory criteria (two pathologi-
calGHstimulationtests)andontheMRIoftheheadwhich
excluded brain tumour and anatomical abnormalities.
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progressive and bitemporal headaches, nausea, vomiting,
diplopia and visual loss. Acute comitant esotropia was the
only abnormality in the neurological examination. Ocular
fundus examination revealed bilateral papilledema and a
lumbar puncture showed an increased intracranial pres-
sure (210 mm H2O) with normal cerebrospinal fluid. An
MRI scan ruled out intracranial lesions (including venous
sinus thrombosis), leading to a final diagnosis of
idiopathic intracranial hypertension (IIH) (pseudotumor
cerebri).
Since the association between IIH and rhGH treatment has
already been described, we promptly discontinued rhGH
and started treatment with acetazolamide at the dose of
20 mg/kg/die. Four days after starting acetazolamide, there
was no clinical improvement at all, with persistence of
headaches, diplopia, nausea, vomitingand weakness. After
two more days, despite increasing the dose of acetazola-
mide up to 30 mg/kg/die, there was no recovery. Indeed,
weakness worsened, arterial blood analysis showed meta-
bolic acidosis (pH 7.29; PCO2 31.1; HCO3 15.7; BE - 7.3),
likely due to acetazolamide. Therefore we stopped
acetazolamide and started the treatment with intravenous
dexamethasone (0.4 mg/kg/die). After only one day there
was a dramatic clinical response with complete disap-
pearance of headache, progressive improvement in the
esotropia and regression of the papilloedema. We
decreased intravenous steroids, switching to oral predni-
sone (1 mg/kg/die) after one week. Ten days after
discharge, the girl no longer had headaches nor weakness,
and there was no more esotropia or diplopia. Eye
examination revealed further improvement of papilloe-
dema. Therapy was tapered down in 3 weeks with no
worsening. After two weeks rhGH was restarted at a dose of
1.8 mg weekly, and progressively increased up to 6 mg
weekly; the treatment was well tolerated, without any side
effects.
Discussion
rhGH has been increasingly described among those
exogene factors responsible for IIH [1-2]. The first cases
were reported in 1986, due to the progressive trend in
higher and more frequent doses of GH following the
introduction of rhGH in 1985. The real incidence of
IIH in children treated with rhGH is not known, since
IIH itself is a rare event in childhood. According to
Australian-New Zealandese OZGROW database, this
incidence is 1.2 per 1000 cases overall, but appears to
be underestimated [3].
It is thought that GH has an IGF-I-mediated action on
choroid plexus, the main site of CSF production, with
increased production of CSF and consequent intracranial
hypertension. Aggressive GH dosing appears to be a
common risk factor in these cases, but the manner in
which GH therapy is initiated might be more important
than the ultimate dose. It is possible that a gradual dose
escalation might eliminate or at least decrease the risk of
IIH in children in rhGH therapy, even if the final achieved
dose is high.
In the majority of cases IIH straightens out within a few
months; however, severe headaches and permanent
severe visual impairments represent two possible com-
plications. Both medical and surgical therapies are
reported, even though - up to now - the efficacy of
treatments for IIH has not been proved: there is
insufficient information to generate an evidence-based
management strategy for IIH, both in adulthood [4] and
for paediatric population [5]. Acetazolamide is largely
recognized as the first-line drug [6], but its efficacy for IIH
and its safety in childhood have not been proven: some
patients might not respond and many Authors report its
unacceptable side-effects [7]. Therefore, comparative,
randomised, prospective studies to quantify the efficacy
and safety of various existing therapeutic options, which
are currently widely used in childhood IIH are urgently
needed.
In this prospective, the use of corticosteroids should be
considered in acute severe cases of IIH when acetazola-
mide is inefficient or intolerable; even if controversial [6],
this strategy is supported - up to now - by single positive
case reports [8,9], including our experience.
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